Literature DB >> 30944118

Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jong Jin Jeong1, Xiaorong Gu2, Ji Nie3, Sriram Sundaravel1, Hui Liu1, Wen-Liang Kuo1, Tushar D Bhagat4, Kith Pradhan4, John Cao1, Sangeeta Nischal4, Kathy L McGraw5, Sanchari Bhattacharyya4, Michael R Bishop1, Andrew Artz1, Michael J Thirman1, Alison Moliterno6, Peng Ji7, Ross L Levine8, Lucy A Godley1, Ulrich Steidl4, James J Bieker9, Alan F List5, Yogen Saunthararajah2, Chuan He3, Amit Verma10, Amittha Wickrema11.   

Abstract

Even though the Ten-eleven translocation (TET) enzymes catalyze the generation of 5-hydroxymethylcytosines required for lineage commitment and subsequent differentiation of stem cells into erythroid cells, the mechanisms that link extracellular signals to TET activation and DNA hydroxymethylation are unknown. We demonstrate that hematopoietic cytokines phosphorylate TET2, leading to its activation in erythroid progenitors. Specifically, cytokine receptor-associated JAK2 phosphorylates TET2 at tyrosines 1939 and 1964. Phosphorylated TET2 interacts with the erythroid transcription factor KLF1, and this interaction with TET2 is increased upon exposure to erythropoietin. The activating JAK2V617F mutation seen in myeloproliferative disease patient samples and in mouse models is associated with increased TET activity and cytosine hydroxymethylation as well as genome-wide loss of cytosine methylation. These epigenetic and functional changes are also associated with increased expression of several oncogenic transcripts. Thus, we demonstrate that JAK2-mediated TET2 phosphorylation provides a mechanistic link between extracellular signals and epigenetic changes during hematopoiesis. SIGNIFICANCE: Identification of TET2 phosphorylation and activation by cytokine-stimulated JAK2 links extracellular signals to chromatin remodeling during hematopoietic differentiation. This provides potential avenues to regulate TET2 function in the context of myeloproliferative disorders and myelodysplastic syndromes associated with the JAK2V617F-activating mutation.This article is highlighted in the In This Issue feature, p. 681. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30944118      PMCID: PMC6697164          DOI: 10.1158/2159-8290.CD-18-1138

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  29 in total

1.  JAK signaling globally counteracts heterochromatic gene silencing.

Authors:  Song Shi; Healani C Calhoun; Fan Xia; Jinghong Li; Long Le; Willis X Li
Journal:  Nat Genet       Date:  2006-08-06       Impact factor: 38.330

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.

Authors:  Fan Liu; Xinyang Zhao; Fabiana Perna; Lan Wang; Priya Koppikar; Omar Abdel-Wahab; Michael W Harr; Ross L Levine; Hao Xu; Ayalew Tefferi; Anthony Deblasio; Megan Hatlen; Silvia Menendez; Stephen D Nimer
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

5.  Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8.

Authors:  Gang G Wang; Katherine R Calvo; Martina P Pasillas; David B Sykes; Hans Häcker; Mark P Kamps
Journal:  Nat Methods       Date:  2006-04       Impact factor: 28.547

6.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.

Authors:  Ann Mullally; Steven W Lane; Brian Ball; Christine Megerdichian; Rachel Okabe; Fatima Al-Shahrour; Mahnaz Paktinat; J Erika Haydu; Elizabeth Housman; Allegra M Lord; Gerlinde Wernig; Michael G Kharas; Thomas Mercher; Jeffery L Kutok; D Gary Gilliland; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

7.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

8.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Authors:  Myunggon Ko; Yun Huang; Anna M Jankowska; Utz J Pape; Mamta Tahiliani; Hozefa S Bandukwala; Jungeun An; Edward D Lamperti; Kian Peng Koh; Rebecca Ganetzky; X Shirley Liu; L Aravind; Suneet Agarwal; Jaroslaw P Maciejewski; Anjana Rao
Journal:  Nature       Date:  2010-12-09       Impact factor: 49.962

9.  KinasePhos: a web tool for identifying protein kinase-specific phosphorylation sites.

Authors:  Hsien-Da Huang; Tzong-Yi Lee; Shih-Wei Tzeng; Jorng-Tzong Horng
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

10.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962

View more
  20 in total

1.  Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.

Authors:  Matthew A Held; Emily Greenfest-Allen; Su Su; Christian J Stoeckert; Matthew P Stokes; Don M Wojchowski
Journal:  Cell Signal       Date:  2020-02-03       Impact factor: 4.315

2.  HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia.

Authors:  John Z Cao; Hui Liu; Amittha Wickrema; Lucy A Godley
Journal:  Blood Adv       Date:  2020-07-14

3.  Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes.

Authors:  Grace A Ward; Kathy L McGraw; Farnoosh Abbas-Aghababazadeh; Benjamin S Meyer; Amy F McLemore; Nicole D Vincelette; Nghi B Lam; Amy L Aldrich; Najla H Al Ali; Eric Padron; Javier Pinilla-Ibarz; Erico Masala; Valeria Santini; Olivier Kosmider; Michaela Fontenay; Pierre Fenaux; Joseph Johnson; Brooke L Fridley; Alan F List
Journal:  Blood Adv       Date:  2021-04-27

4.  Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Authors:  Sriram Sundaravel; Wen-Liang Kuo; Jong Jin Jeong; Gaurav S Choudhary; Shanisha Gordon-Mitchell; Hui Liu; Tushar D Bhagat; Kathy L McGraw; Sandeep Gurbuxani; Alan F List; Amit Verma; Amittha Wickrema
Journal:  Clin Cancer Res       Date:  2019-07-15       Impact factor: 12.531

5.  HOXA9 has the hallmarks of a biological switch with implications in blood cancers.

Authors:  Laure Talarmain; Matthew A Clarke; David Shorthouse; Lilia Cabrera-Cosme; David G Kent; Jasmin Fisher; Benjamin A Hall
Journal:  Nat Commun       Date:  2022-10-03       Impact factor: 17.694

Review 6.  Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease.

Authors:  Christopher S Marnell; Alexander Bick; Pradeep Natarajan
Journal:  J Mol Cell Cardiol       Date:  2021-07-21       Impact factor: 5.000

Review 7.  Epigenetic Dysregulation of Myeloproliferative Neoplasms.

Authors:  Andrew Dunbar; Young Park; Ross Levine
Journal:  Hematol Oncol Clin North Am       Date:  2021-02-05       Impact factor: 3.722

Review 8.  TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.

Authors:  Yihong Guan; Metis Hasipek; Anand D Tiwari; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Semin Hematol       Date:  2020-12-28       Impact factor: 3.851

Review 9.  Epigenetic modifiers in normal and aberrent erythropoeisis.

Authors:  Sriram Sundaravel; Ulrich Steidl; Amittha Wickrema
Journal:  Semin Hematol       Date:  2020-12-29       Impact factor: 3.851

Review 10.  TETology: Epigenetic Mastermind in Action.

Authors:  Ashikh Seethy; Karthikeyan Pethusamy; Indranil Chattopadhyay; Ramkishor Sah; Anita Chopra; Ruby Dhar; Subhradip Karmakar
Journal:  Appl Biochem Biotechnol       Date:  2021-03-10       Impact factor: 2.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.